Contact Us
Frequently Asked Questions
Discover how DIOSynVax are shaping the future of vaccines with cutting-edge technology and investment opportunities. Explore answers to key questions about our mission and progress.
DIOSynVax focuses on combating high-consequence viruses, including influenza, haemorrhagic fever, and coronaviruses like SARS-CoV-2.
By addressing both existing and emerging threats, we aim to deliver broad, long-lasting protection that safeguards global health.
DIOSynVax ensures the safety and efficacy of its vaccines through rigorous research, advanced computational design, and extensive preclinical and clinical testing. Our vaccines are developed using cutting-edge technology to target a broad range of pathogens while minimizing risks. Each vaccine undergoes strict regulatory assessments and clinical trials to meet the highest safety and efficacy standards before approval.
As of January 2025, DIOSynVax has several vaccine candidates in various stages of development. Our coronavirus vaccine candidate is currently undergoing human clinical trials in Southampton and Cambridge. Additionally, we are advancing our vaccine candidates for influenza and hemorrhagic fever viruses through preclinical and clinical development stages